- Home
- TECX vs PRTA Comparison
TECX vs PRTA Comparison
Compare TECX & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TECX
- PRTA
- Stock Information
- Founded
- TECX 2019
- PRTA 2012
- Country
- TECX United States
- PRTA Ireland
- Employees
- TECX N/A
- PRTA N/A
- Industry
- TECX
- PRTA Biotechnology: Pharmaceutical Preparations
- Sector
- TECX
- PRTA Health Care
- Exchange
- TECX Nasdaq
- PRTA Nasdaq
- Market Cap
- TECX 746.6M
- PRTA 765.2M
- IPO Year
- TECX 2018
- PRTA N/A
- Fundamental
- Price
- TECX $29.54
- PRTA $15.56
- Analyst Decision
- TECX Strong Buy
- PRTA Buy
- Analyst Count
- TECX 5
- PRTA 8
- Target Price
- TECX $80.50
- PRTA $46.00
- AVG Volume (30 Days)
- TECX 661.7K
- PRTA 336.3K
- Earning Date
- TECX 03-04-2025
- PRTA 02-20-2025
- Dividend Yield
- TECX N/A
- PRTA N/A
- EPS Growth
- TECX N/A
- PRTA N/A
- EPS
- TECX N/A
- PRTA N/A
- Revenue
- TECX N/A
- PRTA $135,157,000.00
- Revenue This Year
- TECX N/A
- PRTA $56.89
- Revenue Next Year
- TECX N/A
- PRTA N/A
- P/E Ratio
- TECX N/A
- PRTA N/A
- Revenue Growth
- TECX N/A
- PRTA 47.92
- 52 Week Low
- TECX $1.40
- PRTA $11.70
- 52 Week High
- TECX $61.07
- PRTA $31.03
- Technical
- Relative Strength Index (RSI)
- TECX 38.91
- PRTA 59.65
- Support Level
- TECX $30.42
- PRTA $13.69
- Resistance Level
- TECX $36.11
- PRTA $15.09
- Average True Range (ATR)
- TECX 3.49
- PRTA 0.91
- MACD
- TECX -0.94
- PRTA 0.13
- Stochastic Oscillator
- TECX 0.81
- PRTA 68.56
About TECX Tectonic Therapeutic Inc. Common Stock
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).